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The MIST2 trial showed that combined intrapleural use of tissue plasminogen activator (t-PA) and 
DNase was effective when compared to single agents or placebo. However, the treatment costs are 
significant and overall cost-effectiveness of combined therapy remains unclear.  
 
An economic evaluation of the MIST2 trial was performed to assess the cost-effectiveness of 
combined therapy. Costs included were those related to study medications, initial hospital stay, and 
subsequent hospitalisations. Outcomes were measured in terms of life-years gained. All costs were 
reported in Euros (€) and in 2016 prices. 
 
Mean annual costs were lowest in the tPA-DNase group (€10,605 for t-PA, €17,856 for DNase; 
€13,483 for placebo, €7,248 for t-PA-DNase (p=0.209)). Mean 1-year life expectancy was: 0.988 for t-
PA; 0.923 for DNase; and 0.969 for both placebo and t-PA-DNase (p=0.296). Both DNase and 
placebo were less effective, in terms of life-years gained, and more costly than t-PA. When t-PA-
DNase was compared to placebo, the incremental cost per life-year gained of t-PA-DNase was 
€1.6billion, with a probability of 0.85 of t-PA-DNase being cost-effective.  
 
This study demonstrates that combined t-PA-DNase is likely to be highly cost-effective. In light of this 
evidence, a definitive trial designed to facilitate a thorough economic evaluation is warranted to 






Pleural infection is a common and highly morbid condition. The incidence is increasing in both 
children and adults1-5 and outcomes remain poor with up to 20% mortality at 1 year and failure of 
medical therapy in up to 30% of cases.6-10 Median hospital stay is between 12 and 15 days6,7,9,10 and 
we have previously estimated this condition as costing €4,223 per patient.7 Interventions to improve 
drainage, reduce infection and improve outcomes such as need for surgery and time in hospital are 
therefore priorities in care.8  
 
The MIST2 trial was a double blind, double dummy randomised placebo controlled trial assessing the 
combination of intrapleural tissue plasminogen activator (t-PA) and recombinant human 
deoxyribonuclease (DNase) as an adjunct to drainage in patients with pleural infection. This study 
demonstrated significantly improved fluid drainage (radiologically measured) when compared with the 
single use of medications and placebo.7 In secondary outcomes, MIST2 demonstrated t-PA-DNase 
therapy reduced the frequency of surgical referral (OR 0.17, p=0.03) and shortened length of stay in 
hospital.  
 
Since publication of the MIST2 trial, there have been numerous case series of its use as both “rescue 
therapy” and as an alternative to surgery in selected patients, totalling over 500 patients to date.11-20 
However, the costs of t-PA and DNase given twice daily for 3 days (as per the MIST2 protocol) are 
considerable.21 It is not as yet clear if these increased medication costs are offset by reductions in 
surgical referral and shortened length of hospital stay. 
 
This study was therefore conducted to specifically address whether use of t-PA-DNase therapy is 
cost-effective compared with individual use of DNase, t-PA and placebo, using the original data from 





Take home message 
The MIST2 trial showed that combined intrapleural use of t-PA and DNase was effective when 
compared to single agents or placebo in the treatment of pleural infection. This economic evaluation 







Eligibility criteria were clinical evidence of infection and pleural fluid that was macroscopically 
purulent, positive on culture for bacterial infection, or positive for bacteria on Gram's staining, or 
pleural fluid that had a pH of less than 7.2 (measured by means of a blood-gas analyzer). Evidence of 
infection, which was assessed by the recruiting physician, included the presence of fever and 




MIST2 was a double-blind, double-dummy, factorial randomised trial conducted at 11 centres in the 
United Kingdom between December 2005 to November 2008 (ISRCTN57454527).7 As per the study 
protocol patients who did not receive any of the study medications and had pleural opacity at baseline 
that was less than 5% of the hemithorax area on chest radiography were excluded. A total of 210 
adult patients were enrolled into the study and randomised, 55 received double placebo; 52 t-PA, 51 
DNase, 52 t-PA and DNase. Patients were then followed-up for a period of 12 months. The dose of 
DNase was 5mg and the dose of t-PA was 10mg. Intrapleural medications were each given twice 
daily for 3 days, and each administration was followed by clamping of the drain to permit the study 
drug to remain in the pleural space for 1 hour.  
 
Assessments 
The perspective adopted in the economic analysis was that of the hospital provider, with only the 
direct healthcare costs associated with initial hospitalisation, surgery, and subsequent hospitalisation 
over the 12 month follow-up included. All costs were reported in 2016 prices. UK pounds sterling were 
converted to Euros (£1=€0.877, http://ec.europa.eu/Eurostat). 
 
Using information on patients’ trial records, initial hospitalisation length of stay was estimated. This 
was defined as the time between the date of randomisation and discharge to home or to a 
nursing/residential care home. For patients who required thoracic surgery, duration of time in a 
surgical ward was estimated as the time between the date of surgery and date of discharge from 




hospital was valued using the weighted daily average for Healthcare Resource Groups (HRGs) for 
“Lung Abscess and Empyema with Interventions”, which was then multiplied to the patient’s length of 
stay. For patients requiring thoracic surgery, a day in hospital was valued using the weighted daily 
averages of the 3 elective and 3 non-elective HRGs for “Major Thoracic Procedures, 19 years and 
over”. Costs relating to admissions where patients underwent surgical procedures included both the 
cost of the hospital stay and of the procedures captured under that HRG. 
 
From patients’ trial records, information on subsequent hospitalisations over the 12-month follow-up 
were obtained. For each hospitalisation, information on the date of admission and discharge and the 
reason for that admission was recorded. Reasons for admission were translated into International 
Statistical Classification of Diseases and Related Health Problems 10th version (ICD-10) and Office of 
Population Censuses and Surveys Classification of Surgical Operations and Procedures 4th version 
(OPCS-4) codes, which in turn were converted into an HRG using the HRG4+ Reference Cost 
Grouper (NHS Information Centre). HRGs were then valued using NHS Reference Costs.22 Unit costs 
are reported in Table 1. Medication costs were obtained from the British National Formulary.21 Total 
medication costs for each patient were then estimated as follows: for tPA (alteplase) €164 x twice 
daily x three days; and for DNase (pulmozyme) €19 x two doses of 2.5mg x twice daily x three days.  
 
Table 1. Unit costs 
 Unit cost Source 
Study medications, per dose   
Alteplase 10mg €164 British National Formulary 
Pulmozyme 2.5mg €19 British National Formulary 
Initial hospital stays, per day   
Initial stay, non-surgery €502 NHS Reference costs 
Initial stay, surgery €955 NHS Reference costs 
Subsequent admissions   
Hospital stay* €756* NHS Reference costs 
*Weighted-average for the 37 different reasons patients were readmitted during study follow-up. For 





In the absence of prospectively collected health-related quality of life, which would have enabled the 
estimation of Quality Adjusted Life Years (QALYs) gained, we evaluated the impact of the 
interventions on life-years gained. Life-years gained were defined in this study as the number of days 
a patient survived during the year after they were randomised in the study divided by 365.25 days. 
Therefore, for surviving patients a value of 1 life-year gained was assigned.  
 
Statistical analysis 
A within trial economic analysis was undertaken, with total healthcare costs and life years gained per 
patient calculated for the 12 months of the trial period in each of the four groups. Given the time frame 
of the analysis as 1 year, discounting of costs and benefits was not performed. All analyses were 
carried out on an intention to treat basis using StataMP 13. Length of stay in hospital, costs and life-
years gained are reported as means with standard deviations, with differences across the four groups 
compared using analysis of variance. Statistical significance was considered at a p<0.050.  
 
Treatment with chest tube drainage, antibiotics and saline flushes is current practice in the UK 
according to evidence based guidelines (i.e. comparable to placebo in MIST2).8 As a result, we first 
compared each of the 3 trial interventions to placebo. To assess cost-effectiveness we estimated the 
incremental cost-effectiveness ratio (ICER), undertaken by dividing the mean cost difference between 
the placebo and the intervention by the difference in mean life years gained.  
 
In addition, an incremental analysis was conducted, rank ordering each intervention in terms of total 
costs. The mean cost difference between the second least costly intervention and the least costly 
intervention divided by the difference in mean life year gained for these two interventions was used to 
estimate the ICER. Analysis was then repeated in increasing order of cost. 95% confidence intervals 
were derived for the mean cost and life-year gained differences between the groups using non 
parametric bootstrap sampling with 1000 replications. To assess the probability that an intervention 
was cost-effective at different willingness to pay thresholds for an additional life-year gained, cost 




and life-years gained for each of the four interventions.23 An intervention was deemed cost-effective if 
the additional cost per life-year gained was below £30,000 (€34,220).24 
 
A series of one way sensitivity analyses were then performed. As there were a wide number of 
different reasons why patients were readmitted into hospital, each of these reasons varying 
substantially in cost, rather than applying cause-specific unit costs, we applied the weighted average 
unit cost reported in Table 1. As costs of trial medications are likely to vary considerably both in time 
(e.g. introduction of generic versions) and across countries, we varied the costs of medications by 






A total of 210 adult patients were enrolled into the study and randomised: 55 received double 
placebo, 52 t-PA, 51 DNase and 52 t-PA and DNase. However, there was missing length of stay and 
subsequent resource use in 32 patients (7 receiving double placebo, 8 t-PA, 10 DNase, and 7 t-PA 
and DNase) As a result, this analysis is based on the 178 patients having complete resource use: 48 
receiving double placebo; 44 t-PA, 41 DNase, 45 t-PA and DNase.  
 
Resource use, costs and life-years gained 
There were no significant differences across the four groups in terms of initial hospital stays and total 
number of days in hospital over the 12 month period (p=0.265 and p=0.273, respectively). However, 
although not statistically significant, the mean number of days in hospital was lower for the t-PA-
DNase group, in terms of initial hospital stays (both surgical and non-surgical) and hospital 
readmissions (Table 2). 
 









Initial hospital stay, mean (S.D.) 
Number of days, 
non-surgical 
14.48 (20.21) 22.59 (58.74) 23.65 (54.90) 11.43 (9.31) 
Number of days, 
surgical 
2.05 (9.30) 5.66 (18.07) 1.17 (4.36) 0.24 (1.15) 
Number of days, 
total 
16.52 (22.79) 28.24 (61.41) 24.81 (56.11) 11.78 (9.43) 
Subsequent hospital stays, mean (S.D.) 
Patients with 1 or 
more subsequent 
admissions (%) 
3/44 (7%) 1/41 (2%) 4/48 (8%) 1/45 (2%) 
Number of days 0.75 (2.96) 0.75 (4.83) 1.38 (6.54) 0.16 (1.04) 




Number of days 17.27 (24.79) 29.00 (62.01) 26.19 (56.66) 11.93 (9.57) 
 
Except for trial medications, patients randomised to t-PA-DNase had the lowest levels of hospital care 
costs (Table 3). Over the 12-month follow-up period, and after including the costs of medications, 
patients randomised to t-PA-DNase had total costs of €7,248 (S.D. 4,922) compared with €10,605 
(15,413) for t-PA, €17,856 (34,861) for DNase, and €13,483 (28,798) for placebo. Although 
differences in total costs between the four patient groups were not statistically significant (p=0.209), 
patients in the t-PA-DNase group incurred significantly lower costs than patients randomised to 
DNase (p=0.041). Patients randomised to t-PA had the highest number of life-years gained with a 
mean of 0.988 (S.D. 0.081) life-years gained whereas patients randomised to DNase had the lowest 
number with a mean of 0.969 (S.D. 0.147). However, differences in one-year life expectancy were not 
statistically significant across patient groups (p=0.296).  
 









Costs €, mean (S.D.) 
Trial medications 986 (N/A) 227 (N/A) 0 1,213 (N/A) 
Initial hospital stay, 
non-surgical  
7,155 (9,991) 11,164 (27,892) 11,687 (27,133) 5,701 (4,604) 
Initial hospital stay, 
surgical 
1,953 (8,874) 5,401 (17,247) 1,113 (4,159) 234 (1,098) 
Subsequent 
admissions 
511 (2,026) 1,065 (6,820) 682 (2,865) 102 (682) 
Total costs 10,605 (15,413) 17,856 (34,861) 13,483 (28,798) 7,248 (4,922) 
Life-years gained, mean (S.D.) 
Life-years 0.988 (0.081) 0.923 (0.228) 0.969 (0.147) 0.969 (0.153) 
Cost-effectiveness of placebo vs. trial interventions 






N/A 0.81 0.24 0.04 
Cost-effectiveness 
Placebo vs. trial interventions 
Given that placebo is currently standard UK practice in the form of saline flushes, we individually 
compared placebo to each of the three interventions in the trial (Table 3). Placebo was found to be 
dominant over DNase (i.e. it was both more effective and less costly) whereas it was dominated by t-
PA (i.e. placebo was less effective and more costly). When placebo was compared to t-PA-DNase the 
additional cost per life-year gained was €1.6 billion. In this comparison, the probability that t-PA-
DNase was cost-effective at a £30,000 (€34,220) cost per life-year gained threshold was 0.96.  
 
Results of the sensivity analysis showed that varying trial medication costs (reduction of 50% and 
increase of 100%) had no impact on cost-effectiveness. Using the overall mean-weighted unit cost to 
value subsequent days in hospital, rather than cause-specific unit costs, did not impact cost-
effectiveness (Online supplementary material).  
 













t-PA-DNase - - - 0.86 










t-PA both more 
effective and less 
costly 
0.03 




t-PA both more 







*Assuming a cost-effectiveness threshold of £30,000 (€34,220) per life-year gained 
 
When we compared all the interventions in an incremental analysis, we found that DNase and 
placebo were less effective, in terms of life-years gained, and more costly than t-PA. As a result, for 
the incremental cost-effectiveness analysis t-PA was compared to t-PA-DNase, the least costly 
intervention (Table 4). When compared to tPA-DNase, the incremental cost per life-year gained was 
€178,166. This is much higher than the currently recommended willingness to pay thresholds 
recommended by NICE. At a threshold of £30,000 (€34,220) per life year gained, the probability that t-
PA-DNase was cost-effective was 0.86, whereas for t-PA this was 0.12. Placebo and DNase had a 
probability of less than 0.05 of being cost-effective. As shown in Figure 1, at any willingness to pay 
threshold for an additional life-year gained ranging between £0 and £100,000 (€114,000) the 
probability of t-PA-DNase being cost-effective remained above 0.50. For placebo and DNase the 









Using costs collected alongside a randomised clinical trial evaluating intrapleural therapy for 
empyema over a 1 year period, we found that administration of twice daily t-PA-DNase for 3 days was 
most cost-effective compared with t-PA alone, DNase alone or placebo. Despite the added 
medication costs associated with t-PA and DNase, overall costs were lower in the combined 
treatment group than with individual therapies alone, highlighting the benefit seen in the original 
clinical trial in terms of reduced length of stay in hospital and surgical interventions. 
 
This finding is clinically important with potential impact on current treatment. Although the MIST2 
regimen is currently used only in patients who are failing medical therapy for pleural infection, and 
may not have a surgical option in most hospitals, these data suggest that it may be cost effective to 
treat patients with pleural infections with a combination of t-PA and DNase early in treatment. The 
MIST2 trial recruited all patients with pleural infection and began treatment as soon as possible on 
admission, therefore this study provides some economic rationale as to the use of the MIST2 regimen 
in all such cases. Our results suggest that using tPA / DNase in preference to standard care (saline 
flushes, which is equivalent to placebo) in patients with pleural infection might save €5,700 per patient 
treated.  
 
There are limitations to this analysis. Firstly, the economic evaluation was conducted retrospectively 
and not concurrently alongside the clinical trial. The number of patients in each trial group was small, 
with the trial not being designed to detect differences in healthcare costs between the groups. 
Relevant healthcare resource use categories such as use of accident and emergency services, critical 
care, outpatient and primary care were not evaluated. Furthermore, the timeframe of our analysis is 
over 1 year and therefore cost-effectiveness of t-PA-DNase beyond this period is uncertain. However, 
given the acute nature of empyema and its general treatment, it is reasonable to expect that all 
relevant hospitalizations and costs would have been captured in the 1 year follow-up period. 
Prospective follow up data from randomised and observational studies suggest that the majority of 





Quality of life via patient questionnaires was not assessed in this trial and therefore the health 
outcome expressed in our analysis was life years gained. Ideally, in order to assist decision makers in 
choosing amongst different health care interventions, costs per quality adjusted life years (QALYs) 
are typically recommended.6 However, given that combined treatment not only reduced hospitalisation 
stays over the 1-year follow but also reduced surgical interventions, it is likely that quality of life would 
also be higher in the combined treatment group, hence improving the cost-effectiveness of the 
intervention.  
 
Finally, the MIST2 trial was conducted in the UK, using British unit costs to value hospital resource 
use and medications. Therefore, the results presented will be most generalizable to UK settings. 
However, we do believe that our measures of resource use, showing the potential for combined t-PA-
DNase treatment to considerably reduce overall hospital resource use, are likely to be applicable to 
other jurisdictions. 
 
Previous evidence from the MIST2 trial showed that combination treatment with tPA and DNase was 
effective in improving fluid drainage in patients with pleural infection.1 This study now highlights that 
combined treatment is also likely to be highly cost-effective. In light of this evidence, a definitive trial 
designed to facilitate a thorough economic evaluation is therefore warranted to provide further 
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Figure 1. Cost-effectiveness acceptability curve 
 
